CCHF is a serious viral disease with no approved vaccines or treatments. A new mouse study in npj Vaccines, led by a team that includes Scott Pegan at UC Riverside, tested an experimental vaccine. The vaccine uses a harmless virus-like replicon particle that can enter cells but cannot replicate because it lacks the virus genetic material.
The team had shown earlier that one dose could protect animals within three days. In the new work researchers measured antibodies after one or two doses. Antibodies remained detectable for up to 18 months, roughly like several years in humans. A booster produced stronger, more stable antibodies and longer protection. Next steps include large-scale production under Good Manufacturing Practice before human trials, and partners at the CDC are exploring the same platform for other viruses.
Difficult words
- experimental — not fully tested; a new treatment in tests
- replicon — a small virus-like particle used in research
- replicate — to make a copy of itself
- antibody — a blood protein that fights infectionAntibodies
- booster — an extra dose of a vaccine
- detectable — can be found or measured
- protection — the state of being safe from disease
Tip: hover, focus or tap highlighted words in the article to see quick definitions while you read or listen.
Discussion questions
- Do you think it is important to test vaccines in animals before people? Why?
- Would you take a booster if it gave longer protection? Why or why not?
- What information would you want before human trials begin?
Related articles
Low-cost cooling could help Bangladesh garment workers
A University of Sydney study, published in The Lancet Planetary Health on Monday (20 October), tested simple low-cost cooling in a chamber that mimicked extreme factory heat. Fans and water partly restored productivity; a reflective roof cut indoor temperature by 2.5°C.
PAHO issues first guide for tungiasis treatment
PAHO has published the first evidence-based guide to treat tungiasis, recommending low-viscosity dimethicone and warning against unsafe manual removal. The disease affects millions in Latin America, the Caribbean and Sub-Saharan Africa.
